Acorda Expands Alexa Skill Offering for Parkinson’s Awareness Month

ARDSLEY, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq:ACOR)
today announced the launch of The
Many Faces of OFF^℠ Facebook Feed, a new skill for the
Amazon Alexa, as part of the company’s activities in recognition of
Parkinson’s Awareness Month. The skill allows users to ask Amazon Alexa
to include the most recent Acorda post from The Many Faces of OFF
Facebook page as part of their flash news briefing.

Amazon Alexa is Amazon’s cloud-based voice service. For this skill,
users interact with Alexa by asking, “Alexa, what’s in the news?” Alexa
will then include the most recent Acorda post from The Many Faces of OFF
Facebook page during the news briefing.

The
Many Faces of OFF is an online community to share stories that
highlight the impact of OFF periods, or the re-emergence of Parkinson’s
symptoms. Since its launch in September 2016, the community has amassed
more than 37,500 fans who log on to hear stories, see artwork and share
information on the impact of OFF periods.

“Technology continues to drive the way people with Parkinson’s search
for and use information,” said Michael Russo, Executive Director,
Corporate Digital Strategy & Innovation. “At Acorda, we are always
looking for opportunities to provide more information and assistance to
the patient communities we serve and are excited to add The Many Faces
of OFF Facebook feed to the Alexa skills library to keep those impacted
by Parkinson’s up to date on the latest content.”

The Many Faces of OFF is a service mark of Acorda Therapeutics, Inc.

About Parkinson’s Awareness Month

April was officially declared Parkinson’s Awareness Month by the U.S.
Congress in 2009. In addition, 2017 marks 200 years since Parkinson’s
was recognized as a health condition and advocacy organizations and the
global community have come together to #UniteforParkinsons to raise
awareness. For more information, visit www.WorldParkinsonsDay.com.

About Parkinson’s Disease and OFF Periods

Approximately one million people in the U.S. and 1.2 million Europeans
are diagnosed with Parkinson’s disease; OFF periods are experienced by
approximately 350,000 in the U.S. and 420,000 in Europe.

Parkinson’s is a progressive neurodegenerative disorder resulting from
the gradual loss of certain neurons responsible for producing dopamine.
It causes a range of symptoms including impaired movement, muscle
stiffness and tremors. As Parkinson’s progresses, people with
Parkinson’s experience OFF periods, which are characterized by the
re-emergence of Parkinson’s symptoms. This re-emergence can occur even
when an individual’s treatment regimen has been optimized.

OFF periods can be very disruptive to the lives of people with
Parkinson’s, their families and caregivers. OFF periods can increase in
frequency and severity during the course of the disease.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biopharmaceutical company
focused on developing therapies that restore function and improve the
lives of people with neurological disorders. Acorda has a pipeline of
novel neurological therapies addressing a range of disorders, including
Parkinson’s disease, migraine and multiple sclerosis. Acorda markets
three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended
Release Tablets, 10 mg. For more information, please visit the Company’s
website at: www.acorda.com.

Forward-Looking Statement

This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management’s
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: the
ability to realize the benefits anticipated from the Biotie and Civitas
transactions, among other reasons because acquired development programs
are generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to acquired
programs generally improves over time; the ability to successfully
integrate Biotie’s operations and Civitas’ operations, respectively,
into our operations; we may need to raise additional funds to finance
our expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell Ampyra
(dalfampridine) Extended Release Tablets, 10 mg in the U.S., which will
likely be materially adversely affected by the recently announced court
decision in our litigation against filers of Abbreviated New Drug
Applications (each, an “ANDA”) to market generic versions of Ampyra in
the U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including INBRIJA (CVT-301, levodopa inhalation
powder), or any other acquired or in-licensed programs; we may not be
able to complete development of, obtain regulatory approval for, or
successfully market INBRIJA, any other products under development, or
the products that we acquired with the Biotie transaction; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain and maintain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence on
our collaborator Biogen in connection therewith; competition; failure to
protect our intellectual property, to defend against the intellectual
property claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and failure
to comply with regulatory requirements could result in adverse action by
regulatory agencies.

These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this press release are made only as
of the date hereof, and we disclaim any intent or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.

Contacts

Acorda Therapeutics, Inc.
Laura Finley DiBenedetto, 914-326-5427
ldibenedetto@acorda.com